Israeli SaaS Platform NeuroBrave Wraps Funding Round 

The Israeli Software-as-a-Service platform NeuroBrave has landed new investment with the help of the deep tech fund VentureIsrael. 

The startup, which makes an operating system for neuroscience ventures, announced the funding Tuesday (Dec. 28), saying it would use the capital to accelerate research and development and go-to-market activities. 

“NeuroBrave uses cloud-based infrastructure, advanced signal processing and Deep Neural Networks proprietary algorithms, creating a standardized software solution (NeuroSpeed OS™) to provide cognitive states and neuromarkers insights using any hardware, including earphones, smartwatches and many other wearables,” the company said. 

Neuroscience ventures can use its operating system to shorten their time to market by automatically extracting and analyzing their chosen biomarker, thus saving time and money.

“As the world of technology moves toward more and more personalization, NeuroBrave’s solution offering real-time high accuracy insights on cognitive, physiological and mental states is extremely relevant right now,” said Roman Gold, managing general partner of VentureIsrael and now a board observer of NeuroBrave. 

Dror Talisman, CEO and co-founder of NeuroBrave, said the company has also begun to deploy its solution with global companies and small- to medium-sized businesses, “enabling them to provide their users in consumer and professional markets new real-time tools for wellness, productivity, performance and safety by understanding state of mind, emotions and cognitive insights in a very accessible and intuitive way.” 

Talisman added the industry is at an “inflection point” thanks to “Deep Learning, cloud infrastructure and wearable sensors.” 

Read more: FDA Issues Draft Guidance on Digital Health Tech, Seeks Industry Comment By March 2022 

This news comes soon after an announcement by the FDA that it was going to be issuing new guidance for companies creating health monitoring hardware and software. 

“Advances in sensor technology, general-purpose computing platforms and methods for data transmission and storage have revolutionized the ability to remotely obtain and analyze clinically relevant information from individuals,” the FDA said last week. 

At the same time, this technology could present cyber security risks, the agency added, “that could potentially impact the functionality of the [digital health technologies] and/or compromise patient privacy. Accordingly, sponsors should consider FDA information on cybersecurity to ensure that data can be securely stored and transmitted.”